Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

GeneNews completes US$2 million non-brokered private placement

Fasken
Reading Time 1 minute read Subscribe
Client

GeneNews Limited

On August 10, 2009, GeneNews Limited (TSX: GEN) completed the final tranche of a non-brokered private placement offering of common shares. The private placement was fully subscribed resulting in the issuance of an aggregate of 8,000,000 common shares from treasury at a price of $0.25 per share, for total gross proceeds in the amount of $2,000,000. GeneNews is a molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. GeneNews was advised in this transaction by a team from Fasken Martineau that included Geoff Clarke, Brad Freelan and Charles Todd (corporate/securities).

    Subscribe

    Receive email updates from our team

    Subscribe